Zealand Pharma A/S ZLDPF

Company Overview

Zealand Pharma A/S is a Danish biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines, primarily targeting metabolic diseases, obesity, rare diseases, and gastrointestinal disorders. The company operates within the global biopharmaceutical industry and concentrates on therapies that leverage peptide engineering and receptor biology to address chronic conditions with significant unmet medical need. Its revenue has historically been generated through licensing agreements, collaboration payments, milestone payments, and research partnerships, while it continues advancing wholly owned and partnered drug candidates through clinical development.

The company was founded in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma evolved from an early-stage peptide research company into a clinical-stage biotechnology enterprise with multiple late-stage and mid-stage therapeutic programs. Its strategic positioning is tied to expertise in peptide therapeutics and long-acting formulations, particularly within obesity and metabolic disease treatment markets. The company has built collaborations with major pharmaceutical companies to support development, commercialization, and global market reach.